Skip to content
Peptide research

Zinc Thymulin (ZnFTS)

Also known as Facteur Thymique Serique · Thymulin
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A zinc-bound form of thymulin, a thymic hormone that is inactive without zinc, promoted for immune restoration and hair regrowth. The zinc-deficiency study supports zinc repletion to restore endogenous thymulin activity, rather than treatment with exogenous zinc-thymulin. Most other evidence is animal or mechanistic, so the human case is weak. Human safety evidence includes a small topical pilot; this does not establish injectable or long-term safety, and its immune-stimulating action poses a theoretical autoimmune risk. Not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Restoration of endogenous thymulin activity during zinc repletion; this study did not test exogenous zinc-thymulin treatment

    Medium

    Human trials show zinc repletion restores thymulin activity and corrects T-cell measures in deficient adults.

  • Promotion of hair growth in androgenetic alopecia

    Speculative

    One small unblinded 2017 pilot of topical zinc-thymulin reported less shedding, with no controlled replication.

  • Analgesic and anti-inflammatory effects comparable to standard drugs

    Low

    In rat models a thymulin analogue matched standard anti-inflammatory drugs, with no human testing yet.

Evidence limits

Evidence Level
Mostly Preclinical

Zinc thymulin has a robust preclinical evidence base spanning in vitro, animal, and limited human studies, published in high-impact peer-reviewed journals including Nature, Journal of Clinical Investigation, and British Journal of Pharmacology. The immunological mechanism of action is well-characterized: thymulin requires zinc for activity, promotes T-cell differentiation, and serves as a sensitive biomarker of zinc status. Human evidence includes Prasad's 1988 JCI study demonstrating zinc-dependent thymulin restoration in zinc-deficient adults, and the Vickers 2017 pilot study showing topical efficacy in androgenetic alopecia (n=18, open-label, no placebo control). Historical randomized placebo-controlled trials tested synthetic thymulin, called nonathymulin, in rheumatoid arthritis. Those studies do not establish efficacy of contemporary zinc-thymulin products for hair loss or immune aging. Analgesic and neuroprotective effects are supported by multiple animal studies but no human pain trials. Gene therapy restoration of thymulin has been demonstrated in thymectomized rodents only. No studies are registered on ClinicalTrials.gov for any indication. The fundamental science is strong, but translational clinical evidence remains limited.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No Phase I safety trials conducted in humans

    High
  • Immune-stimulating; theoretical autoimmune aggravation

    Theoretical
  • Injection site irritation

    Low
  • No reproductive toxicology studies conducted

    Moderate
  • Crosses into brain tissue; documented CNS activity

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.